Pyc Therapeutics Ltd has released a press release.
PYC Increases Ownership of VP-001 Program
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- PYC Receives FDA Fast Track Designation
- Successful Toxicology Results Pave Way for Phase 2 Trial
- First patient dosed in eye disease clinical trial
- Placement Supporting Document
- Successful Completion of $30m Placement
Later from PYC Therapeutics
- RP11 Clinical Trial Dosing Completed In Patient Cohort 1
- Safety Review Committee Approves Dose Escalation
- PYC-001 Effective In Both NHPs and Patient-Derived Models
- RP11 Clinical Trial Dosing Completed In Patient Cohort 2
- PYC and FDA Align On Clinical Trial Pathway in ADOA
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics